Pfizer
5,036.30
-31.50(-0.62%)
Market Cap₹23,039.93 Cr
PE Ratio27.55
IndustryHealthcare
Company Performance:
1D-0.62%
1M+1.36%
6M-9.42%
1Y+4.84%
5Y-3.62%
View Company Insightsright
More news about Pfizer
11Aug 25
Pfizer Introduces Advanced 20-Valent Pneumococcal Vaccine for Adults in India
Pfizer Limited has introduced its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV20) for adults in India. The vaccine offers protection against 20 serotypes of Streptococcus pneumoniae, surpassing previous conjugate vaccines in coverage. Administered as a single dose, it targets adults 18 years and older, particularly those over 50 and individuals with comorbidities. The vaccine aims to address the growing need for adult immunization in India and reduce the burden of pneumococcal disease.
20May 25
Pfizer: Q4 Profit Soars 85%, Stock Surges 12%
Pfizer Ltd reported an 85% increase in net profit to ₹330.94 crore for Q4, with revenue growing 8.3% to ₹591.91 crore. EBITDA rose 20% to ₹227.50 crore, with the margin expanding to 38.4%. The company declared a final dividend of ₹35 per share, leading to a 12% surge in stock price to ₹4,990.
19May 25
Pfizer India Announces Robust Dividends and Q4 Financial Results
Pfizer India has released its Q4 financial results, showing significant growth. The company's revenue increased by 8.23% to ₹592.00 crore, while EBITDA grew by 20.63% to ₹228.00 crore. Net profit surged by 84.92% to ₹331.00 crore, partly due to an exceptional item of ₹173.00 crore. The EBITDA margin improved by 378 basis points to 38.43%. Pfizer India also announced a total dividend of ₹165.00 per share, including a final dividend of ₹35.00 and special dividends of ₹100.00 and ₹30.00. Despite strong Q4 results, annual figures showed a moderate decline in revenue and profitability compared to the previous fiscal year.
24Feb 25
Pfizer Ltd Shares Surge 8% on Marketing Deal with Mylan, Despite Q3 Profit Dip
Pfizer Ltd's shares rose over 8% following a 5-year sales and marketing agreement with Mylan Pharmaceuticals for CNS therapy brands Ativan and Pacitane in India. This surge occurred despite a slight decline in Q3 FY2024 results, with revenue down 0.51% to ₹580.8 crore and net profit falling 1.85% to ₹127.6 crore year-on-year. The partnership aims to leverage Mylan's marketing network to boost sales of these CNS medications in the Indian market.
21Feb 25
Pfizer Ltd Inks Marketing and Supply Deal with Mylan for Two Key Brands
Pfizer Limited has entered a 5-year marketing and supply agreement with Mylan Pharmaceuticals for two established brands, Ativan and Pacitane, in the Indian market. The strategic partnership aims to leverage Mylan's expertise in the Central Nervous System (CNS) therapy area, enhancing distribution and specialist engagement. This collaboration is expected to boost the in-clinic presence of Pfizer's products without significant additional investment.
Pfizer
5,036.30
-31.50
(-0.62%)
1 Year Returns:+4.84%
Industry Peers
Sun Pharmaceutical
1,737.00
(-1.08%)
Divis Laboratories
6,496.50
(+0.31%)
Torrent Pharmaceuticals
3,834.30
(+0.37%)
Cipla
1,496.30
(-0.29%)
Dr Reddys Laboratories
1,265.80
(-1.38%)
Lupin
2,107.00
(-0.31%)
Zydus Life Science
917.80
(-1.08%)
Mankind Pharma
2,193.30
(-1.63%)
Aurobindo Pharma
1,211.40
(-0.54%)
Alkem Laboratories
5,566.00
(-0.55%)